MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?

摘要

In this context, MYC in concert with BCL6 and BCL2 appear to have a role to play in refractory/relapsed DLBCL. MYC translocation is a defining feature for Burkitt lymphoma (BL) and is required for the diagnosis. However, emerging data showed that MYC gene aberrations are not limited to BL because DLBCL and other lymphomas can also harbor this genetic abnormality. In DLBCL, MYC aberration is found in less than 10% of the cases at diagnosis6 and in almost 20% at first relapse.